Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients
Author:
Open Access
- 1 July 2010
- journal article
- review article
- Published by Taylor & Francis in Lung Cancer: Targets and Therapy
- Vol. 1, 85-100
Abstract
Peer reviewed article authored by (Jean Jacques Dugoua, Ping Wu, Dugald Seely, et al). Read article or submit your manuscript for publishing.Keywords
This publication has 36 references indexed in Scilit:
- Randomized trials published in some Chinese journals: how many are randomized?Trials, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- [Clinical effect of yiqi yangyin jiedu decoction in treating patients with advanced non-small cell lung cancer].2008
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group TrialJournal of Clinical Oncology, 2001
- Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering ResultsJournal of Clinical Oncology, 2001
- Operating Characteristics of a Rank Correlation Test for Publication Bias1994
- Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo.1988
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Combination of log relative risk in retrospective studies of disease.American Journal of Public Health and the Nations Health, 1966